vs
FirstCash Holdings, Inc.（FCFS）とUNITED THERAPEUTICS Corp（UTHR）の財務データ比較。上の社名をクリックして会社を切り替えられます
UNITED THERAPEUTICS Corpの直近四半期売上が大きい（$790.2M vs $501.3M、FirstCash Holdings, Inc.の約1.6倍）。UNITED THERAPEUTICS Corpの純利益率が高く（46.1% vs 20.8%、差は25.3%）。FirstCash Holdings, Inc.の前年同期比売上増加率が高い（21.2% vs 7.4%）。過去8四半期でFirstCash Holdings, Inc.の売上複合成長率が高い（16.9% vs 8.0%）
FirstCash Holdings, Inc.は米国テキサス州フォートワースに本社を置く質屋事業を営む企業で、米国国内及びラテンアメリカ各地で小売型質店を展開しています。ナスダック証券取引所に上場しており、南北アメリカ全域に広範な事業基盤を有しています。
ユナイテッド・セラピューティクスは米国のバイオテクノロジー企業で、異種移植を含む臓器移植関連の医薬品や技術を開発しています。主力製品の多くは肺疾患治療や臓器製造分野向けで、メリーランド州とノースカロライナ州に2つの本社を置き、米国各地やカナダにも拠点を構えています。
FCFS vs UTHR — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $501.3M | $790.2M |
| 純利益 | $104.2M | $364.3M |
| 粗利率 | — | 86.9% |
| 営業利益率 | 28.5% | 45.1% |
| 純利益率 | 20.8% | 46.1% |
| 売上前年比 | 21.2% | 7.4% |
| 純利益前年比 | 24.7% | 20.9% |
| EPS（希薄化後） | $2.35 | $7.66 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $501.3M | $790.2M | ||
| Q3 25 | $411.0M | $799.5M | ||
| Q2 25 | $385.1M | $798.6M | ||
| Q1 25 | $371.1M | $794.4M | ||
| Q4 24 | $413.7M | $735.9M | ||
| Q3 24 | $363.1M | $748.9M | ||
| Q2 24 | $363.5M | $714.9M | ||
| Q1 24 | $366.8M | $677.7M |
| Q4 25 | $104.2M | $364.3M | ||
| Q3 25 | $82.8M | $338.7M | ||
| Q2 25 | $59.8M | $309.5M | ||
| Q1 25 | $83.6M | $322.2M | ||
| Q4 24 | $83.5M | $301.3M | ||
| Q3 24 | $64.8M | $309.1M | ||
| Q2 24 | $49.1M | $278.1M | ||
| Q1 24 | $61.4M | $306.6M |
| Q4 25 | — | 86.9% | ||
| Q3 25 | — | 87.4% | ||
| Q2 25 | — | 89.0% | ||
| Q1 25 | — | 88.4% | ||
| Q4 24 | — | 89.7% | ||
| Q3 24 | — | 88.9% | ||
| Q2 24 | — | 89.1% | ||
| Q1 24 | — | 89.2% |
| Q4 25 | 28.5% | 45.1% | ||
| Q3 25 | 27.4% | 48.6% | ||
| Q2 25 | 21.1% | 45.6% | ||
| Q1 25 | 30.0% | 48.2% | ||
| Q4 24 | 26.5% | 48.6% | ||
| Q3 24 | 23.5% | 45.8% | ||
| Q2 24 | 18.2% | 44.7% | ||
| Q1 24 | 22.3% | 52.6% |
| Q4 25 | 20.8% | 46.1% | ||
| Q3 25 | 20.1% | 42.4% | ||
| Q2 25 | 15.5% | 38.8% | ||
| Q1 25 | 22.5% | 40.6% | ||
| Q4 24 | 20.2% | 40.9% | ||
| Q3 24 | 17.9% | 41.3% | ||
| Q2 24 | 13.5% | 38.9% | ||
| Q1 24 | 16.7% | 45.2% |
| Q4 25 | $2.35 | $7.66 | ||
| Q3 25 | $1.86 | $7.16 | ||
| Q2 25 | $1.34 | $6.41 | ||
| Q1 25 | $1.87 | $6.63 | ||
| Q4 24 | $1.86 | $6.23 | ||
| Q3 24 | $1.44 | $6.39 | ||
| Q2 24 | $1.08 | $5.85 | ||
| Q1 24 | $1.35 | $6.17 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $125.2M | $2.9B |
| 総負債低いほど良い | $2.2B | — |
| 株主資本純資産 | $2.3B | $7.1B |
| 総資産 | $5.3B | $7.9B |
| 負債/資本比率低いほどレバレッジが低い | 0.98× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $125.2M | $2.9B | ||
| Q3 25 | $130.2M | $2.8B | ||
| Q2 25 | $101.5M | $3.0B | ||
| Q1 25 | $146.0M | $3.3B | ||
| Q4 24 | $175.1M | $3.3B | ||
| Q3 24 | $106.3M | $3.3B | ||
| Q2 24 | $113.7M | $3.0B | ||
| Q1 24 | $135.1M | $2.7B |
| Q4 25 | $2.2B | — | ||
| Q3 25 | $2.2B | — | ||
| Q2 25 | $1.7B | — | ||
| Q1 25 | $1.7B | — | ||
| Q4 24 | $1.7B | — | ||
| Q3 24 | $1.7B | — | ||
| Q2 24 | $1.7B | — | ||
| Q1 24 | $1.5B | — |
| Q4 25 | $2.3B | $7.1B | ||
| Q3 25 | $2.2B | $6.6B | ||
| Q2 25 | $2.1B | $7.2B | ||
| Q1 25 | $2.1B | $6.8B | ||
| Q4 24 | $2.1B | $6.4B | ||
| Q3 24 | $2.0B | $6.1B | ||
| Q2 24 | $2.0B | $5.7B | ||
| Q1 24 | $2.0B | $5.3B |
| Q4 25 | $5.3B | $7.9B | ||
| Q3 25 | $5.2B | $7.4B | ||
| Q2 25 | $4.5B | $7.9B | ||
| Q1 25 | $4.4B | $7.7B | ||
| Q4 24 | $4.5B | $7.4B | ||
| Q3 24 | $4.4B | $7.1B | ||
| Q2 24 | $4.3B | $6.7B | ||
| Q1 24 | $4.2B | $6.5B |
| Q4 25 | 0.98× | — | ||
| Q3 25 | 1.01× | — | ||
| Q2 25 | 0.79× | — | ||
| Q1 25 | 0.83× | — | ||
| Q4 24 | 0.85× | — | ||
| Q3 24 | 0.87× | — | ||
| Q2 24 | 0.85× | — | ||
| Q1 24 | 0.75× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $206.6M | $346.2M |
| フリーキャッシュフロー営業CF - 設備投資 | — | $173.3M |
| FCFマージンFCF / 売上 | — | 21.9% |
| 設備投資強度設備投資 / 売上 | — | 21.9% |
| キャッシュ転換率営業CF / 純利益 | 1.98× | 0.95× |
| 直近12ヶ月FCF直近4四半期 | — | $1.0B |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $206.6M | $346.2M | ||
| Q3 25 | $135.8M | $562.1M | ||
| Q2 25 | $116.9M | $191.7M | ||
| Q1 25 | $126.6M | $461.2M | ||
| Q4 24 | $198.1M | $341.2M | ||
| Q3 24 | $113.1M | $377.2M | ||
| Q2 24 | $106.2M | $232.2M | ||
| Q1 24 | $122.5M | $376.5M |
| Q4 25 | — | $173.3M | ||
| Q3 25 | — | $351.6M | ||
| Q2 25 | — | $129.5M | ||
| Q1 25 | — | $386.3M | ||
| Q4 24 | — | $254.5M | ||
| Q3 24 | — | $300.7M | ||
| Q2 24 | — | $187.1M | ||
| Q1 24 | — | $338.3M |
| Q4 25 | — | 21.9% | ||
| Q3 25 | — | 44.0% | ||
| Q2 25 | — | 16.2% | ||
| Q1 25 | — | 48.6% | ||
| Q4 24 | — | 34.6% | ||
| Q3 24 | — | 40.2% | ||
| Q2 24 | — | 26.2% | ||
| Q1 24 | — | 49.9% |
| Q4 25 | — | 21.9% | ||
| Q3 25 | — | 26.3% | ||
| Q2 25 | — | 7.8% | ||
| Q1 25 | — | 9.4% | ||
| Q4 24 | — | 11.8% | ||
| Q3 24 | — | 10.2% | ||
| Q2 24 | — | 6.3% | ||
| Q1 24 | — | 5.6% |
| Q4 25 | 1.98× | 0.95× | ||
| Q3 25 | 1.64× | 1.66× | ||
| Q2 25 | 1.95× | 0.62× | ||
| Q1 25 | 1.51× | 1.43× | ||
| Q4 24 | 2.37× | 1.13× | ||
| Q3 24 | 1.74× | 1.22× | ||
| Q2 24 | 2.16× | 0.83× | ||
| Q1 24 | 2.00× | 1.23× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
FCFS
| US Pawn Segment | $292.2M | 58% |
| Retail POS Payment Solutions | $209.8M | 42% |
UTHR
| Tyvaso DPI | $338.6M | 43% |
| Remodulin | $128.0M | 16% |
| Nebulized Tyvaso | $125.7M | 16% |
| Orenitram | $121.2M | 15% |
| Unituxin | $62.3M | 8% |
| Adcirca | $7.8M | 1% |
| Other | $6.6M | 1% |
